摘要
目的探讨布地奈德气雾剂治疗支气管哮喘急性发作的效果及对气道炎性反应的影响。方法选取我院2014年11月至2015年12月收治的支气管哮喘急性发作患者80例,随机分为研究组和对照组。对照组给予沙丁胺醇雾化剂治疗,研究组联合布地奈德气雾剂治疗。观察和比较两组患者的临床疗效、肺功能、血清炎性指标以及不良反应的发生率。结果研究组的临床总有效率显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的肺功能VC、FEV1%等指标水平均改善,但研究组的肺功能VC、FEV1%等指标水平均优于对照组,差异具有统计学意义(P<0.05);研究组的血清ESR、痰Eos、CRP水平明显低于对照组,具有统计学意义(P<0.05);两组均未出现严重的不良反应。结论布地奈德气雾剂治疗支气管哮喘急性发作的效果显著,肺功能改善明显,不良反应和炎性反应发生率降低,值得临床推广应用。
Objective To explore the effect of budesonide aerosol treatment on bronchial asthma of acute attack and influence on airway inflammatory reaction. Methods 80 cases of patients with bronchial asthma of acute attack admitted to our hospital from November 2014 to December 2015 were randomly divided into study group and control group, with 40 cases in each group. The control group was treated with salbutamol aerosol, while the study group was treated with budesonide aerosol on this basis. The clinical effect, pulmonary function, serum inflammatory indicators and incidence of adverse reactions were observed and compared between two groups. Results The clinical total effective rate of study group was significantly higher than that of control group, with statistical difference （P 〈0.05）. After treatment, the levels of VC and FEV~% of two groups improved, but the improvement of levels of VC and FEV1% of study group were better than those of control group, with statistical differences （P 〈0.05）. The serum ESR, sputum Eos and CRP level of study group were significantly lower than those of control group, with statistical differences （P〈0.05）. No serious adverse reactions appeared in two groups. Conclusions Budesonide aerosol on the treatment of bronchial asthma of acute attack has significant effect and can improve lung function with lower incidence of adverse reactions and inflammatory reactions, which is worthy of clinical promotion and application.
出处
《临床医学工程》
2016年第11期1485-1486,共2页
Clinical Medicine & Engineering
关键词
布地奈德气雾剂
支气管哮喘急性发作
炎性反应
Budesonide aerosol
Bronchial asthma of acute attack
Inflammatory reaction
